Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Weiz – page 11

435 clinical trials in Weiz, Austria. Every trial is listed in the EU Clinical Trials Register and updated daily.

Weiz at a glance
435
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

435 trials in Weiz

Open in trial search

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab
  • Sponsor:F. Hoffmann-La Roche AG

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbH

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Busulfan
  • Sponsor:Medical Center - University Of Freiburg

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Study on Letrozole Maintenance Therapy for Patients with Epithelial Ovarian Cancer

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Letrozole
  • Sponsor:Swiss GO Trial Group

Myelofibrosis

Recruiting

Study on Adding Navtemadlin to Ruxolitinib for Patients with Myelofibrosis and Suboptimal Response to Ruxolitinib

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Navtemadlin
  • Sponsor:Kartos Therapeutics Inc.

Study on the Effects of Ticagrelor and Acetylsalicylic Acid in Patients with Coronary Artery Disease Undergoing CABG Surgery

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Weill Medical College Of Cornell University

Medulloblastoma

Recruiting

Study on Medulloblastoma Treatment in Children Aged 3-5 Using Carboplatin and Drug Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:University Medical Center Hamburg-Eppendorf

Breast cancer

Recruiting

Study on the Effectiveness and Safety of Saruparib and Camizestrant in Adults with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Astrazeneca AB

Hypoxia+2

Recruiting

Oxygen Therapy to Prevent Breathing Problems After Non-Cardiac Surgery in Patients at Risk for Postoperative Complications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Oxygen
  • Sponsor:Medical University Of Graz

Study on Atezolizumab and Bevacizumab for Patients with Intermediate-Stage Liver Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Medulloblastoma

Recruiting

Study of drug combination therapy for high-risk medulloblastoma in patients over 3 years of age: carboplatin, cisplatin, cyclophosphamide, lomustine, temozolomide, thiotepa, vincristine

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria

Clinical research in Weiz

What the registry says about research in the country

01 Breast Cancer Research

Clinical trials focusing on hormone receptor-positive (HR+) and HER2-negative breast cancer, investigating innovative therapeutic approaches for patients with high recurrence risk.

  • Node-positive breast cancer treatment
  • Endocrine therapy optimization
  • Early-stage breast cancer management

Research aims to improve disease-free survival rates through targeted therapeutic interventions.

02 Endocrine Therapy Studies

Investigating the effectiveness of elacestrant compared to standard endocrine treatments for breast cancer patients, with a focus on improving long-term outcomes.

  • Comparative treatment efficacy
  • Invasive cancer-free survival
  • Gender-inclusive research

Studies evaluate novel therapeutic approaches for both women and men with hormone-sensitive breast cancer.

03 Advanced Treatment Protocols

Evaluation of palbociclib in combination with standard endocrine therapy, exploring enhanced treatment strategies for early-stage breast cancer.

  • Combination therapy assessment
  • Long-term treatment outcomes
  • Risk reduction strategies

Research focuses on improving standard treatment protocols through innovative drug combinations.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.